knowledge -WSS

knowledge

author：explore 2025-10-01 23:04:14 - browse：69383

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： FDA advisers back CAR

focus

WSS

EPA limits use of carcinogenic gas for sterilizing medical devices

Cybersecurity threat forces Lurie Children's to take systems offline

Biden administration opens offers in Medicare drug price negotiations

The real point of Kenneth Smith’s execution by nitrogen gas

WuXi out of biotech trade group, U.S. and China relations to blame

General Catalyst, Summa Health deal will turn on physician buy

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

Medicare drug price negotiation’s day in court

Guidelines to prevent youth baseball injuries need more muscle

Why scientists need input from humanists on sensitive research

Malaria cases in Florida and Texas: Here’s what you need to know

What we need to know about Arena Bioworks

In age of alternative facts, a scholarly course on calling out crap

As AI in medicine takes off, can 'human in the loop' prevent harm?

Medical records are filled with copy

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

hotspot

WuXi out of biotech trade group, U.S. and China relations to blame

Quicker fix for pulse oximeters urged during FDA public meeting

HHS secretary Becerra pressed on Change HealthCare cyberattack

Why depression after traumatic brain injury is distinct

Juul spent big to court Black leaders to promote its e

Steward Health Care Massachusetts hospitals face fiscal disaster

explore

leisure time

focus

hotspot